Please login to the form below

Not currently logged in

Takeda launches new business in China

Will serve as hub for importing medicines from across the world

Takeda has launched a new division in China to serve as a hub for importing the company's products from its manufacturing sites across the world.

The establishment of Takeda (China) International Trading (TCIT) follows the Japan-based company's decision last year that it would invest in emerging markets to cope with the loss of patent protection for its blockbuster diabetes drug Actos (pioglitazone).

Takeda had already made headway in China before that announcement through its 2011 purchase of Nycomed, which operated in the country through its Nycomed Shanghai business and its 2010 acquisition of Guangdong Techpool Bio-Pharma.

TCIT will begin operations this month, with 500 employees of Nycomed Shanghai to be transferred to the new business and other operations owned by Takeda in China.

Following this restructure, Nycomed Shanghai is then due to be liquidated by the end of March 2015.

“Our new business structure will simplify our distribution processes and improve our efficiency to better serve patients in this huge and important market,” said Haruhiko Hirate, corporate officer and head of North Asia of Takeda.

“In conjunction with the recent opening of our development centre in Shanghai, we are now best equipped to bring new products to Chinese patients as early as possible.”

According to Takeda, China is currently the company's seventh largest market with top line growth expected to grow by a compound annual growth rate (CAGR) of 29 per cent between the financial years 2012 and 2016.

In addition to its Nycomed purchase, other recent investments in the area include the announcement last year it intended to create the Takeda Shanghai Development Center to expand the company's clinical development activities in Asia. In 2010, Takeda also expanded both its manufacturing and sales activities by taking full control of Tianjin Takeda - formerly a part-owned joint venture.

23rd January 2013

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Conversis Medical

Conversis Medical is a translation company specialising in translation and localisation for the medical industry, particularly in clinical trial projects....

Latest intelligence

A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018